The European Medicines Agency is this week considering applications from two companies seeking the coveted accelerated assessment review pathway for their new products.
[MSD] and Astellas Pharma should learn this week whether the European Medicines Agency will grant their investigational products targeting Ebola and acute myeloid leukemia (AML) respectively fast-track status when they are eventually submitted for regulatory review.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) is scheduled to deliberate on applications for accelerated assessment from...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
